Concentrations of 3a-reduced neuroactive steroids are altered in depression and normalize after antidepressant pharmacotherapy with selective serotonin re-uptake inhibitors (SSRIs). We investigated the impact of mirtazapine on the activity of a key neurosteroidogenic enzyme, the 3a-hydroxysteroid dehydrogenase (3a-HSD), and on the levels of neuroactive steroids in relation to clinical response. A total of 23 drug-free in-patients suffering from a major depressive episode (DSM-IV criteria) underwent 5-week treatment with mirtazapine (45 mg/ day). Plasma samples were taken weekly at 0800 and quantified for neuroactive steroids by means of combined gas chromatography/mass spectrometry analysis. Enzyme activity was determined by assessment of steroid conversion rates. Irrespective of clinical outcome, there were significant increases in 3a,5a-tetrahydroprogesterone, 3a,5b-tetrahydroprogesterone, 5a-dihydroprogesterone, and 5b-dihydroprogesterone after mirtazapine treatment, whereas 3b,5a-tetrahydroprogesterone levels were significantly decreased. In vitro investigations demonstrated a dose-dependent inhibitory effect of mirtazapine on the activity of the microsomal 3a-HSD in the oxidative direction (conversion of 3a,5a-tetrahydroprogesterone to 5a-dihydroprogesterone). Mirtazapine affects neuroactive steroid composition similarly as do SSRIs. The inhibition of the oxidative pathway catalyzed by the microsomal 3a-HSD is compatible with an enhanced formation of 3a-reduced neuroactive steroids. However, the changes in neuroactive steroid concentrations more likely reflect direct pharmacological effects of this antidepressant rather than clinical improvement in general.
Introduction
Certain 3a-reduced metabolites of progesterone such as 3a,5a-tetrahydroprogesterone (3a,5a-THP, 5a-pregnan-3a-ol-20-one, allopregnanolone) and 3a,5b-tetrahydroprogesterone (3a,5b-THP, 5b-pregnan-3a-ol-20-one, pregnanolone) are potent positive allosteric modulators of the g-aminobutyric acid A (GABA A ) receptor complex. [1] [2] [3] It has been shown that the selective serotonin re-uptake inhibitor fluoxetine may enhance the formation of 3a,5a-THP in different areas of the rat brain. 4, 5 Moreover, the decline of 3a,5a-THP after bilateral removal of the olfactory bulb in rats can be reversed by chronic treatment with different antidepressants. 6 Thus, normalization of 3a,5a-THP levels may contribute to the antidepressant-like effect of these drugs in the olfactory-bulbectomy rat model of depression via an upregulation of the GABAergic tone. 6 In rat studies investigating the impact of mirtazapine on the composition of neuroactive steroids, conflicting results were observed insofar, as mirtazapine significantly increased cerebrospinal and plasma levels of 3a,5a-THP after a single injection but not after long-term administration. 7 Administration of 3a,5a-THP to animals subjected to the Porsolt forced swim test extended the time of swimming before immobility, indicating that 3a,5a-THP itself might possess antidepressant-like effects in mice. 8 In line with these preclinical findings, there is evidence that neuroactive steroids might also contribute to the pathophysiology of depression in humans and its treatment by antidepressant drugs. During depression, the concentrations of 3a,5a-THP and 3a,5b-THP are decreased, whereas the levels of 3b,5a-tetrahydroprogesterone (3b,5a-THP, 5a-pregnan-3b-ol-20-one, isopregnanolone), a stereoisomer of 3a,5a-THP, which may act as an antagonist for GABAergic steroids, 2 are increased. 9 Treatment with both selective serotonin re-uptake inhibitors (SSRIs) 9, 10 and tricyclic antidepressants 9 normalized this disequilibrium of neuroactive steroids throughout several weeks. However, non-pharmacological antidepressant treatment strategies such as partial sleep deprivation, 11 repetitive transcranial magnetic stimulation, 12 or electroconvulsive therapy 13 did not affect the concentrations of neuroactive steroids, irrespective of the clinical response. These data suggest that the reported changes in neuroactive steroid levels following antidepressant pharmacotherapy more likely reflect specific pharmacological effects of the antidepressant drugs on neurosteroidogenic enzymes rather than clinical improvement in general.
The 5a-reductase catalyzes the reduction of progesterone into 5a-dihydroprogesterone (5a-DHP), which is an irreversible reaction in mammalian cells. 14, 15 5a-DHP is further reduced to 3a,5a-THP by the 3a-hydroxysteroid dehydrogenase (3a-HSD), which controls the amount of 3a,5a-THP in the brain. 16, 17 In fact, it has been suggested that various SSRIs may shift the activity of 3a-HSD toward the reductive direction, thereby enhancing the formation of 3a-reduced metabolites of progesterone. 18 3a-HSD activity has been described in the cytosolic and microsomal fractions of a number of human and animal tissues. 17, [19] [20] [21] [22] [23] [24] [25] To date, at least four types of cytosolic 3a-HSDs have been identified in humans (also called AKR1C1-AKR1C4), which display 3-, 17-, and 20-ketosteroid reductase activity. All of these cytosolic enzymes exhibit a preference for the phosphorylated nucleotides as cofactors (NADP þ , NADPH). [26] [27] [28] AKR1C1 (in particular, 20a-HSD activity and only weak 3a-HSD activity) and predominantly AKR1C2 (3a-HSD type 3) are the only enzymes out of the aldo-keto reductase (AKR) superfamily with 3-ketosteroid reductase activity in humans, which are expressed in the CNS in a relevant amount. 27, 28 In contrast to cytosolic 3a-HSDs, microsomal enzymes with 3a-HSD activity strongly prefer NAD þ /NADH as cofactors. [28] [29] [30] The predominant forms of nucleotide cofactors in the cells are NAD þ and NADPH. 28, [31] [32] [33] Although both cytosolic and microsomal 3a-HSDs in principle can act bidirectionally in vitro, in the living brain, cytosolic 3a-HSDs are expected to almost exclusively catalyze the reductive pathway (conversion of 5a-DHP into 3a,5a-THP; cofactor: NADPH) whereas microsomal 3a-HSDs are expected to catalyze the oxidation of 3a,5a-THP into 5a-DHP (cofactor: NAD þ ), owing to the intracellular availability of the respective cofactors.
Mirtazapine is an antidepressant agent with a unique mechanism of action, which does not inhibit the re-uptake of norepinephrine or serotonin but acts as an antagonist of a 2 , 5-HT 2 , 5-HT 3 , and histamine H 1 receptors 34 and might also differ in its impact on neurosteroidogenesis as compared to tricyclics or SSRIs. Therefore, we chose mirtazapine as a pharmacological agent in our study to clarify whether there is an influence of this antidepressant on the concentrations of neuroactive steroids in humans. Moreover, as no data are available so far as to whether changes in neuroactive steroid concentrations after antidepressant pharmacotherapy are related to clinical response and may differ between responders and non-responders, we investigated the impact of mirtazapine treatment on plasma neuroactive steroid composition in relation to the clinical outcome in depressed patients. In addition, we assessed the effects of mirtazapine on the cytosolic and microsomal 3a-HSD activity in in vitro investigations of human recombinant proteins.
Materials and methods

Subjects
A total of 23 drug-free depressed in-patients (four men, 19 women) aged between 22 and 71 years (mean age 52.26711.92 years) entered the study after the procedures had been fully explained and written informed consent had been obtained. The patients were diagnosed by experienced and trained psychiatrists according to DSM-IV criteria using the Structured Clinical Interview for DSM-IV, German version. 35 Inclusion criteria for the depressed patients were (a) a major depressive episode according to DSM-IV criteria (bipolar disorder not included), (b) a sum score of at least 18 on the 21-item version of the Hamilton Depression Rating Scale (21-HAMD), 36 (c) exclusion of major medical disorders, availability of normal laboratory parameters, normal blood pressure, normal electrocardiogram, and normal encephalogram, (d) exclusion of addiction or other comorbid psychiatric diagnoses, (e) no psychotropic drugs for at least 5 days before and throughout the study, with the exception of chloralhydrate in case of sleep difficulties; in particular, no concomitant use of benzodiazepines, (f) exclusion of pregnancy or use of oral contraceptives, and (g) no use of angiotensin-converting enzyme inhibitors, oral steroid hormones, or hormonal replacement therapy, which may influence the levels of neuroactive steroids. Out of the 23 patients included in the study, five patients did not receive any psychopharmacological pretreatment (being drug-free for at least 35 days) when entering the study. None of the patients had been pretreated with fluoxetine, mood stabilizers or neuroleptics. Eight patients had been pretreated with tricyclic antidepressants, six patients with SSRIs, one patient with reboxetine, one patient with venlafaxine, and two patients with St John's wort (Table 1) . Further clinical characteristics are also given in Table 1 .
Study design
Following a wash-out period of at least 5 days, the patients were treated with mirtazapine at a standard dosage of 45 mg/day for 5 weeks. The administration of mirtazapine was titrated at the beginning of the study in that the patients received 15 mg mirtazapine at 2200 on day 0, 30 mg mirtazapine on day 1 (15 mg at 0800, 15 mg at 2200), and 45 mg mirtazapine/day (15 mg at 0800, 30 mg at 2200) from day 2 to the end of the study (day 35). In case of sleep difficulties, chloralhydrate (up to 1000 mg/day) was allowed as concomitant medication. Plasma samples were taken before mirtazapine therapy and every week thereafter at 0800 (days 0, 7, 14, 21, 28, 35) for quantification of neuroactive steroids. Severity of depression was estimated weekly (days 0, 7, 14, 21, 28, 35) using the 21-HAMD in the morning between 0900 and 1100. All raters were experienced psychiatrists and blind to measurements of neuroactive steroids. Clinical response was defined by a reduction of at least 50% in the 21-HAMD sum score after 5 weeks of treatment with mirtazapine.
The study was carried out according to the fifth revision of the Declaration of Helsinki 37 and had been approved by a local ethics committee.
Quantification of neuroactive steroids in depressed patients Plasma samples were taken at 0800 on the study days 0, 7, 14, 21, 28, and 35. On day 0, plasma samples were taken at 0800 and the first mirtazapine dosage (15 mg) was administered at 2000. The plasma samples were quantified for neuroactive steroids (progesterone, 5a-dehydroprogesterone (5a-DHP = 5a-pregnan-3,20-dione), 5b-dehydroprogesterone (5b-DHP = 5b-pregnan-3,20-dione), 3a,5a-THP ( = 5a-pregnan-3a-ol,20-one = allopregnanolone), 3a,5b-THP ( = 5b-pregnan-3a-ol-20-one = pregnanolone), and 3b,5a-THP ( = 5a-pregnan-3b-ol-20-one = isopregnanolone)) by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis (GC/ MS) after extraction with ethyl acetate, as described earlier. 38 The detection limit was approximately 10 fmol. All neuroactive steroid concentrations are given as mean7s.e.m.
Measurement of mirtazapine serum concentrations in depressed patients
After 2 and 5 weeks of treatment, the mirtazapine and desmethyl-mirtazapine (DM-mirtazapine) concentrations were determined using the same blood samples as for measurement of neuroactive steroids (at 0800). The detection of mirtazapine and DM-mirtazapine was accomplished by an isocratic reversed-phase There was a wash-out period of at least 5 days before the study. Data represent mean7s.d. M: males; F: females; prem.: pre-menopausal females; postm.: post-menopausal females; MAP: mean arterial blood pressure;
serum concentrations of mirtazapine, desmethyl-mirtazapine, and the sum of both (nmol/l).
high-performance liquid chromatography (HPLC) separation and ultraviolet (UV) detection at 214 nm. The HPLC system consisted of a Waters 515 pump, a Waters 717 autosampler, and a Waters 2487 dualwavelength UV detector (Waters, Milford, MA, USA). The chromatographic separation was achieved by using an end-capped C18 reversed-phase HPLC column (Merck, Darmstadt, Germany) connected with a guard column (Merck, Darmstadt, Germany). Benperidol, kindly provided by Bayer Healthcare (Leverkusen, Germany), was used as an internal standard. Mirtazapine and its desmethyl metabolite were kindly provided by Organon (Oss, The Netherlands). Stock solutions of the analytes (1 mg/ml) were prepared in methanol and added to human drug-free serum obtained from healthy donors to establish five different calibration concentrations. The standard curves for mirtazapine and its metabolite DM-mirtazapine ranged from 5 to 100 ng/ml. The five-point calibration curves were plotted by the peak-high ratios (peak area for mirtazapine and DM-mirtazapine) of each analyte/internal standard versus concentrations of the respective analyte in serum.
The mean inter-day precision of 7.5 and 7.6% for mirtazapine and DM-mirtazapine, respectively, was determined by analyzing 10 control samples at a concentration of 40 ng/ml. The limits of quantification were 2.5 ng/ml for mirtazapine and 1.25 ng/ml for DM-mirtazapine. The efficiency of the solid-phase extraction was determined with a quality control sample at a level of 80 ng/ml. The absolute recovery of mirtazapine and DMmirtazapine from serum was 88 and 84%, respectively. It was obtained as the peak-high response of the processed samples, expressed as a percentage of the response of the calculated amount of the substances prepared in H 2 O directly injected onto the HPLC, which corresponds to the 100% recovery. SI units (nmol/l) were calculated considering the molecular weights of mirtazapine (265.36) and DMmirtazapine (250.34).
In vitro investigations studying the impact of mirtazapine on the activity of microsomal 3a-HSD and cytosolic 3a-HSD type 3
Materials. Steroid standards ( > 98% purity) were purchased from Fluka Chemie GmbH (Buchs, Switzerland Enzymatic reactions of human cytosolic 3a-HSD type 3. Pure recombinant human cytosolic 3a-HSD type 3 protein was expressed in Escherichia coli and refolded and purified from bacterial inclusion bodies. 5a-DHP reduction was conducted in 100 ml reaction systems containing 100 mM sodium phosphate (pH 7.4), 4 mg of recombinant enzyme, 2 mM NADPH, and 2.5 mM [ 3 H]-5a-DHP (40 000 c.p.m.) in 4% acetonitrile. For inhibition experiments, the reaction mixtures (without steroidal substrate) were preincubated for 30 min at 371C with mirtazapine at different concentrations (1, 10, 50 mM). Reactions were then initiated by the addition of the respective substrate and were incubated at 371C for 25 min. The selected reaction conditions afforded a rate of product accumulation within the linear range of the enzymatic conversion. Following the incubation, the reactions were quenched with 400 ml of ice-cold ethyl acetate. The resulting organic extracts were evaporated to dryness under a gentle stream of nitrogen and re-dissolved in hexane and injected into the HPLC for analysis. Negative control reactions omitting cofactor (NADPH) or enzyme were carried out in order to exclude any non-enzymatic conversion. In all instances, the control reactions resulted in no detectable product formation.
Enzymatic reactions of human microsomal 3a-HSD.
The cDNA for human microsomal 3a-HSD 30 was kindly provided by Dr Natalia Y Kedishvili (University of Missouri-Kansas City) and was stably expressed in HEK-293 cells. Cells were grown and maintained at 371C in an oxygen/CO 2 95:5 atmosphere in DMEM/HAM F-12 1:1 (Invitrogen, Basel, Switzerland) supplemented with 10% fetal bovine serum (Invitrogen, Basel, Switzerland) and 300 mg/ml G-418 (Catalys AG, Wallisellen, Switzerland). For the enzyme inhibition experiments, cells were preincubated with mirtazapine at different concentrations (1, 10, 50, 100, 200 mM) for 30 min at 371C. [ 3 H]-3a,5a-THP (40 000 c.p.m.) was added to the medium (2 ml) and the incubation was continued for 2 h at 371C. Following the incubation, the media and the cells were transferred to 15 ml plastic Falcon tubes on ice, sonicated for 15 s, and extracted with 3 ml of icecold ethyl acetate. Following centrifugation at 1500 r.p.m., the organic layer was removed and processed as above for the HPLC analysis. Negative control reactions in media without cells were carried out, without any detectable product formation and thereby excluding any non-enzymatic conversion. The flow rate was held constant at 1 ml/min. Sample injection volume was 1 ml. Column efflux was directly introduced into a 500 TR Series radioflow scintillation detector (Packard Biosciences, Meriden, CT, USA). Liquid scintillation cocktail Flo-Scint A (Perkin Elmer Life Sciences, Huenenberg, Switzerland) was used for the radioflow detector.
Statistical analysis
of present episode, duration of wash-out period, 21-HAMD sum score week 0). Moreover, the total duration of in-patient status (including the participation in the study) was compared between responders and non-responders using the two-tailed t-test for independent samples.
Normal distribution of the data was established using the Kolmogorov-Smirnov test. For statistical comparisons of mean steroid concentrations before and during mirtazapine treatment (week 0-5) and between responders and non-responders, multivariate analysis (MANOVA) with a repeated-measures design was performed. Thereby, 'time' (week 0-5) and 'group' (response versus non-response) were considered as within-subjects and between-subjects factors with six ('time') and two ('group') levels, respectively. Moreover, to analyze a possible impact of previous treatment on the concentrations of neuroactive steroids, a repeated-measures MANOVA was also carried out using 'time' (six levels: week 0-5) and 'group' (four levels: no previous treatment; previous treatment with tricyclics, SSRIs, and other antidepressants) as within-subjects and between-subjects factors without differentiating between responders and nonresponders. In addition, to compare mirtazapine and DM-mirtazapine concentrations and the sum of both between responders and non-responders, repeatedmeasures ANOVAs were also performed: (a) withinsubjects factor: 'time' with three levels: week 0, 2, and 5; (b) between-subjects factor: 'group' with two levels: responders versus non-responders). When a significant factor effect was found in the MANOVAs, univariate F-tests followed to identify those neuroactive steroids that contributed significantly to these effects. For these steroids, tests with contrasts were additionally performed when 'time' was among the significant influential factors. For the MANOVA procedures, a correction was applied to the F-value by means of adjusting the degrees of freedom by a factor Epsilon, if the sphericity test (Mauchly W test) was significant indicating a heterogeneity of covariances (Huyn-Feldt correction). Moreover, Pearson's correlation coefficient was used as a parameter to test for significant correlations between the percentage changes in neuroactive steroids and the percentage reduction in 21-HAMD scores (global sum score; sum of 'sleep' items 4-6 (insomnia early, middle, and late); item 9 (agitation); sum of 'anxiety' items 10 (psychic anxiety) and 11 (somatic anxiety)) after 5 weeks of mirtazapine treatment. In addition, correlations between mirtazapine and DM-mirtazapine levels at week 5 and the percentage changes of neuroactive steroids were tested about significance using Pearson's correlation coefficient. The ratios 3a,5a-THP/5a-DHP and 3a,5b-THP/5b-DHP were calculated to further analyze the conversion of 5a-DHP and 5b-DHP toward the reductive direction and were tested for significant associations with 21-HAMD sum score reduction and the levels of mirtazapine and DMmirtazapine. With respect to the in vitro investigations, t-tests for dependent samples were performed comparing the effects of each concentration of mirtazapine to the vehicle (dimethyl sulfoxide).
As a nominal level of significance, a = 0.05 was accepted. The software program SPSS version 12.0.1 was used for data analysis.
Results
Clinical study in depressed patients
A total of 12 patients (two men, 10 women) responded to 5-week treatment with mirtazapine (45 mg/day), whereas the other 11 patients (two men, nine women) were non-responders (21-HAMD sum score reduction < 50%; Table 1 ). At baseline, responders and nonresponders did not differ significantly either in gender distribution (Fisher's exact test: P = 1.000) or with respect to type of pretreatment (w 2 = 0.009; d.f. = 1; P = 0.924; Table 1 ), nor were there any differences between responders and non-responders with regard to age, height, weight, mean arterial blood pressure, age of onset, number of episodes, duration of present episode, duration of wash-out period, or 21-HAMD sum score at week 0 (two-sided t-test for independent samples: P > 0.05; Table 1 ). However, the total duration of the in-patient status (including the participation in the study) was significantly longer in non-responders than in responders (non-responders: 91.27724.33 days; responders: 46.58717.16 days; P < 0.001).
Using MANOVA with a repeated-measures design (Wilks multivariate tests of significance), the type of pretreatment (four levels: no pretreatment, tricyclics, SSRIs, or other antidepressants) did not have any significant impact on the concentrations of neuroactive steroids during the study (no significant 'group' effect: F (18, 40 .083) = 1.362; P = 0.204). Moreover, the mirtazapine serum levels, the DM-mirtazapine serum concentrations, and the sum of both did not differ significantly between responders and non-responders (again no significant 'group' effects in the repeatedmeasures ANOVAs; mirtazapine: F (1, 21) = 2.721, P = 0.114; DM-mirtazapine: F (1, 21) = 0.015, P = 0.905; mirtazapine þ DM-mirtazapine: F (1, 21) = 1.315, P = 0.264) although mirtazapine concentrations were slightly lower in responders than in non-responders (Table 1) . These slight differences in mirtazapine levels also did not reach statistical significance when t-tests for independent samples were used to compare responders and non-responders either at week 2 or at week 5 (P > 0.05). When analyzing the steroid levels in responders and non-responders to 5-week treatment with mirtazapine, the repeated-measures MANOVA revealed a significant 'time' effect (F (30, 402) = 5.180; P < 0.001). Using univariate F-tests (Huyn-Feldt correction applied), this 'time' effect could be attributed to a significant increase in 3a,5a-THP (F (3.306, 69.426) = 15.928; P < 0.001), a significant increase in 3a,5b-THP (F (4.669, 98.054) = 17.519; P < 0.001), a significant decrease in 3b,5a-THP (F (3.873, 81.336) = 7.162; P < 0.001), and also slight but significant increases in both 5a-DHP (F (4.285, 89.990) = 4.092; P < 0.01) and 5b-DHP (F (4.698, 98.659) = 5.245; P < 0.001), whereas progesterone levels did not change significantly (F (4.273, 89.725) = 0.442; P = 0.790) (Figure 1) . Remarkably, the 3a,5a-THP and 3a,5b-THP concentrations reached their maximum levels already after 3 weeks of mirtazapine treatment and nearly did not change further during the remaining 2 weeks. Compared with the baseline values (week 0), tests with contrasts pointed out significant differences during week 3-5 for 3a,5a-THP and 3a,5b-THP (week 3, 4, 5: P < 0.05,, as compared with week 0), whereas the concentrations of 3b,5a-THP, 5a-DHP, and 5b-DHP did not differ significantly before week 4 (week 4, 5: P < 0.05, as compared to week 0). There was neither a significant 'group' effect (F (6, 16) = 0.666; P = 0.678) nor a significant 'time' Â 'group' interaction effect (F (30, 402) = 1.369; P = 0.097), that is, the demonstrated changes in the concentrations of neuroactive steroids during 5-week mirtazapine treatment were comparable in responders and non-responders (Figure 1) . The increase in 3a-reduced neuroactive steroids and the decrease in 3b,5a-THP were similar when pre-and postmenopausal women, or men were considered separately (data not shown).
No significant correlations could be shown between the percentage 21-HAMD sum score reduction and the percentage changes in neuroactive steroids (3a,5a-THP, 3a,5b-THP, 3b,5a-THP, 5a-DHP, 5b-DHP) after 5 weeks of mirtazapine treatment (P > 0.05). As all correlation tests revealed P-values > 0.10, not even a trend could be observed. Moreover, the percentage increase in the ratios 3a,5a-THP/5a-DHP and 3a,5b-THP/5b-DHP did not correlate significantly with the percentage 21-HAMD sum score reduction after 5 weeks of treatment (P > 0.05). The lack of a significant association between the rises in 3a,5a-THP or 3a,5b-THP and the 21-HAMD sum score reduction is depicted in Figure 2 . Furthermore, the increase in neuroactive steroids was not significantly associated with a concomitant decrease in 21-HAMD sub-items representing certain depressive symptoms (sum of 'sleep' items 4-6; item 9 (agitation); sum of 'anxiety' items 10 and 11). With regard to the mirtazapine and DM-mirtazapine levels and the percentage changes in neuroactive steroids at week 5, significant associations could be demonstrated: there was a significant positive correlation between the percentage increase in 3a,5a-THP and both the mirtazapine levels (r = 0.494; P = 0.017) and the sum of mirtazapine and DM-mirtazapine concentrations (r = 0.429; P = 0.041) and a significant positive correlation between the percentage increase in 3a,5b-THP and the DMmirtazapine levels (r = 0.414; P = 0.049) (Figure 2 ). Using the ratios 3a,5a-THP/5a-DHP and 3a,5b-THP/ 5b-DHP, the associations with mirtazapine and its metabolite DM-mirtazapine became even stronger: the percentage increase in 3a,5a-THP/5a-DHP correlated significantly with mirtazapine levels (r = 0.534; P = 0.009) and the sum of mirtazapine and DMmirtazapine levels (r = 0.484; P = 0.019) at week 5, whereas the percentage increase in 3a,5b-THP/5b-DHP after 5 weeks of treatment correlated significantly with DM-mirtazapine concentrations (r = 0.454; P = 0.030) (Figure 2 ). No significant associations were found between the percentage changes in the other steroids measured (3b,5a-THP, 5a-DHP, 5b-DHP) and the mirtazapine or DM-mirtazapine levels at week 5 (P > 0.05).
In vitro investigations Although in vitro both cytosolic and microsomal 3a-HSD may work in the reductive as well as in the oxidative direction, the equilibrium of the respective direction is largely determined by the presence of the respective cofactors. In vivo, the cytosolic 3a-HSD utilizes NADPH as cofactor and works almost only in the reductive direction, whereas in the living brain the cofactor for microsomal 3a-HSD is NAD þ , being the cofactor for the oxidative pathway. [28] [29] 33 Therefore, we determined the effects of mirtazapine on the reduction of 5a-DHP catalyzed by the cytosolic 3a-HSD type 3 and on the oxidation of 3a,5a-THP catalyzed by the microsomal 3a-HSD.
Mirtazapine did not affect the reductive reaction (conversion of 5a-DHP to 3a,5a-THP) of the cytosolic 3a-HSD type 3 expressed in E. coli not even at 50 mM concentrations (P > 0.05; Figure 3a) . However, in a HEK-293 cell line stably expressing recombinant human microsomal 3a-HSD, incubation with mirtazapine at different concentrations significantly inhibited the oxidative reaction (conversion of 3a,5a-THP to 5a-DHP) of this enzyme in a concentration-dependent fashion with an IC 50 value of 46 mM (1 mM: not significant; 5 mM: not significant; 10 mM: P < 0.05; 50 mM: P < 0.05; 100 mM: P < 0.001; 200 mM: P < 0.001; Figure 3b ).
Discussion
Similar to SSRIs, 9,10 treatment with mirtazapine increases the concentrations of the GABAergic 3a-reduced metabolites of progesterone (3a,5a-THP, 3a,5b-THP) throughout several weeks in depressed patients in view of a significant decline of 3b,5a-THP levels. Remarkably, the maximal mirtazapine-induced increase in 3a,5a-THP and 3a,5b-THP was achieved already within 3 weeks of treatment, although the patients, in particular the responders, showed a continuous improvement of their depressive symptoms up to the end of the observation period (week 5). Because of circadian fluctuations in the concentrations of progesterone and its metabolites, 39 neuroactive steroids were quantified at the same time point (0800) on each study day (week 0-5) in our investigation. The mirtazapine-induced changes in neuroactive steroids were not related to the type of psychopharmacological pretreatment. Moreover, responders and non-responders to mirtazapine treatment were comparable with respect to gender distribution and other demographic and clinical variables. The slightly but nonsignificantly higher mirtazapine levels in non-responders compared to responders despite the same dosage (45 mg/day) Figure 1 Concentrations of 3a,5a-THP (a), 3a,5b-THP (b), 3b,5a-THP (c), 5a-DHP (d), 5b-DHP (e), and progesterone (f) in non-responders (n = 11) and responders (n = 12) to mirtazapine treatment (45 mg/day) on week 0 up to week 5. Data represent the mean7s.e.m. P-values of univariate F-tests are indicated. *Significant difference compared with week 0 in tests with contrasts.
might be related to genetic polymorphisms in the cytochrome P450 enzymes CYP1A2, CYP2D6, and CYP3A4, which catalyze the biotransformation of mirtazapine into its two major metabolites 8-OHmirtazapine and DM-mirtazapine 40, 41 and which might differ accidentally between responders and non-responders in our sample. We did not observe increased sedative side effects in non-responders compared to responders. This finding is in line with the study of Grasmader et al., 42 who found that Figure 2 Scatterplots of the percentage change in 3a,5a-THP and the percentage change in 21-HAMD sum score (a), the percentage change in 3a,5b-THP and the percentage change in 21-HAMD sum score (b), the percentage change in 3a,5a-THP and the mirtazapine levels (c), the percentage change in 3a,5b-THP and the DM-mirtazapine levels (d), the percentage change in 3a,5a-THP/5a-DHP and the mirtazapine levels (e), and the percentage change in 3a,5b-THP/5b-DHP and the DMmirtazapine levels (f) in 23 depressed patients after 5 weeks of mirtazapine treatment (45 mg/day). Pearson's correlation coefficients and P-values are indicated. Percentage changes: a positive value represents an increase and a negative value a decrease.
mirtazapine-induced sedative side effects appear predominantly during the first week and do not correlate with plasma concentrations after several weeks of treatment.
The assumption that the effects of mirtazapine on the composition of neuroactive steroids are due to direct pharmacological properties of this antidepressant is supported by the positive correlation between the increases in 3a,5a-THP, 3a,5a-THP/5a-DHP, 3a,5b-THP, or 3a,5b-THP/5b-DHP and the mirtazapine or DM-mirtazapine levels at week 5. However, the influence of 5-week treatment with mirtazapine on the concentrations of neuroactive steroids is apparently not related to the clinical outcome, as, in our study, the changes in neuroactive steroids were similar in responders and non-responders to mirtazapine therapy. Moreover, in contrast to SSRIs (fluoxetine, fluvoxamine), which yielded an increase in 3a,5a-THP levels in the cerebrospinal fluid of 15 depressed patients, which was significantly correlated with the decrease in the HAMD score in a former investigation, 10 in our study no such association could be demonstrated between 21-HAMD sum score reduction and the mirtazapine-induced changes of plasma neuroactive steroid composition.
Our findings therefore challenge the hypothesis that the correction of the disequilibrium in the composition of neuroactive steroids after antidepressant treatment is related to a favorable clinical response. The consistent finding of increased 3a,5a-THP levels after acute or subchronic treatment with SSRIs both in animals 4, 6 and humans 9,10 strongly supports the view of direct biochemical and pharmacological effects of antidepressants on neurosteroidogenesis and the corresponding enzymes. Moreover, in our present study, mirtazapine-induced changes in neuroactive steroids (increase of 3a,5a-THP and 3a,5b-THP, decrease of 3b,5a-THP) occurred similarly in responders and non-responders and were not correlated with an amelioration of depressive symptoms. In addition, studies of non-pharmacological antidepressant treatment options such as repetitive transcranial magnetic stimulation, 12 partial sleep deprivation, 11 or electroconvulsive therapy 13 did not detect any changes in the composition of progesterone metabolites, not even in responders with a pronounced and sustained alleviation of depressive symptoms. 13 These data suggest that the normalization of the presumed disequilibrium of neuroactive steroids in depression is not a prerequisite for antidepressant efficacy of the respective treatment strategy. Apparently, neither do drug-induced changes in the composition of plasma neuroactive steroids ensure antidepressant response as shown in the present study, nor does the lack of effect on the concentrations of neuroactive steroids as seen after non-pharmacological treatment strategies [11] [12] [13] preclude therapeutic efficacy.
It is noteworthy that, in an animal study, fluoxetine increased the 3a,5a-THP biosynthesis without changing the brain content of its precursor 5a-DHP. 4 However, in our investigation in depressed patients, the mirtazapine-induced increase in 3a,5a-THP concentrations was paralleled by a weak but significant enhancement also of 5a-DHP levels. Therefore, a slight impact of mirtazapine on the activity of the human 5a-reductase, which irreversibly catalyzes the reduction of progesterone to 5a-DHP, cannot be excluded. Interestingly, the rate of brain biosynthesis of both 5a-DHP and 3a,5a-THP is decreased to about 30% in socially isolated mice, an animal model of depression, which suggests that 5a-DHP may also play a certain role in the pathophysiology of depression and related psychiatric disorders. 43, 44 While 5a-DHP is a ligand for progesterone receptors, which act as transcription factors in the regulation of gene expression, 45 also withdrawal 46, 47 or administration of 3a,5a-THP 48 may alter the expression of GABA A receptor subunits, for example, the a 4 -or d-subunits, thereby affecting GABA A receptor function.
It has been suggested that SSRIs may elevate the formation of 3a-reduced neuroactive steroids via shifting the activity of the cytosolic 3a-HSD type 3 toward the reductive direction. 18 However, another Figure 3 Impact of mirtazapine at different concentrations on the activities of both human cytosolic 3a-HSD type 3 (reductive pathway) (a) and human microsomal 3a-HSD (oxidative pathway) (b). Reductive pathway: 5a-DHP conversion to 3a,5a-THP; oxidative pathway: 3a,5a-THP conversion to 5a-DHP. Data are presented as mean7s.e.m. of at least three independent experiments and are indicated as % vehicle (conversion rates obtained in the vehicle are set at 100%). *Statistical significance at the P < 0.05 level; ***Statistical significance at the P < 0.001 level.
study, which did not find any change in the activity of this enzyme after administration of various SSRIs, suggested that the interference with the 3a-HSD type 3 might not be the crucial mechanism by which fluoxetine increases 3a,5a-THP concentrations. 49 In our study, we could not detect a significant effect of mirtazapine on the reductive activity of the cytosolic 3a-HSD type 3. However, in our investigation, we show for the first time an impact of an antidepressant drug such as mirtazapine on a microsomal isoform of the 3a-HSD, which in vivo catalyzes the oxidation of 3a,5a-THP to 5a-DHP. 30 Indeed, mirtazapine inhibited the oxidative activity of the microsomal 3a-HSD in a concentration-dependent manner, with an IC 50 value of 46 mM, which may contribute to the enhanced formation of 3a-reduced metabolites of progesterone in our study. It has to be considered that our in vitro investigations of the cytosolic 3a-HSD type 3 [26] [27] [28] and the microsomal 3a-HSD as described by Chetyrkin et al. 30 do not exclude the possibility that mirtazapine exerts even more pronounced effects on other 3a-HSD isoforms. Moreover, the IC 50 value of 46 mM for the mirtazapine-induced inhibition of the oxidative activity of the microsomal 3a-HSD exceeds the concentrations of mirtazapine in the brain, which are, in rat studies, in a low micromolar range. 50 Nevertheless, our observation of a concentration-dependent inhibition of microsomal 3a-HSD activity by mirtazapine is at least compatible with the increase of 3a-reduced neuroactive steroids in depressed patients treated with this antidepressant.
Taken together, mirtazapine is capable of affecting neuroactive steroid composition in a similar way as do SSRIs. The inhibition of the oxidative pathway catalyzed by the microsomal 3a-HSD is compatible with an enhanced formation of 3a-reduced neuroactive steroids. However, the mirtazapine-induced changes in neuroactive steroid concentrations more likely reflect direct pharmacological effects of this antidepressant rather than clinical improvement in general. In previous investigations with SSRIs, no separate analysis for responders and non-responders has been performed 9,10,51 and, currently, it is not known whether similar changes in neuroactive steroids occur in non-responders to SSRI treatment. The lack of any significant association between mirtazapine-induced changes in neuroactive steroids and improvement of depressive symptoms in our investigation differs from animal studies suggesting that depression-like behaviors in animal models of depression such as protracted social isolation, 43 the forced Porsolt swim test, 8 or bilateral olfactory bulbectomy 52 are associated with a decrease in 3a,5a-THP and treatment of the animals with antidepressant drugs may both reverse the decline in 3a,5a-THP and improve the depression-like behavior. 6, 8, 44 This discrepancy between animal studies and our clinical investigation in human beings indicates that modelling human mental disorders in experimental animals has to be interpreted with caution with regard to the clinical situation. 53, 54 Meta-analyses indicate that the superiority of antidepressant drugs over placebo is rather small 55, 56 and the true benefits of short-term active treatment in depressed patients are narrow. 57 Hence, it may require large sample sizes to detect differences in biological parameters between responders and non-responders in a 5-week trial reflecting the mechanism of successful antidepressant pharmacotherapy. Regarding the limited sample size in our study, we cannot exclude that a differential impact of mirtazapine on neuroactive steroids in responders and non-responders might become obvious when investigating a greater number of depressed patients. Nevertheless, in our sample, the clear pharmacological effect of mirtazapine on neuroactive steroid composition without any significant relationship to antidepressant effectiveness is striking. Further studies including larger samples of patients are needed to clarify whether the increase in 3a-reduced neuroactive steroids during antidepressant pharmacotherapy may contribute to the alleviation of certain depressive symptoms, such as amelioration of anxiety, inner tension, or sleep disturbances.
